Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEE321 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Healthy Subjects (Part A) | EXPERIMENTAL | CEE321 0.2% (3 mg/cm2) topical cream b.i.d. |
| Atopic Dermatitis (Part B) | EXPERIMENTAL | CEE321 0.2% (3 mg/cm2) topical cream b.i.d. |
| Name | Type | Description |
|---|---|---|
| CEE321 | DRUG | CEE321 administered to all subjects |
Key inclusion Criteria for Healthy Subjects (Part A) * Written informed consent * Able to communicate well with the investigator to understand and comply with the requirements of the study, including skin biopsies * Healthy male and female subjects aged ≥18 and ≤ 65 years * Able to comply with requ...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
CEE321 is an investigational small molecule being developed for atopic dermatitis, a chronic inflammatory skin condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in adult subjects with atopic dermatitis.
CEE321 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the safety and tolerability of this investigational drug.
CEE321 is in Phase 1 clinical development. A first-in-human study has been completed, and the drug remains investigational. It has not received regulatory approval and is not yet available for clinical use outside of research settings.
CEE321 has been studied in one clinical trial with the identifier NCT04612062, titled 'A First-in-Human Study of CEE321 in Adult Subjects.' This Phase 1 study enrolled 28 participants with atopic dermatitis and was conducted in the United States and Japan. The trial has been completed.
CEE321 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for atopic dermatitis. The completed first-in-human study was designed to evaluate safety and tolerability, but the drug has not yet demonstrated efficacy or received marketing authorization.